The once-daily, long-acting beta2-agonist (LABA) approved in the US is an inhaled, steroid-free chronic obstructive pulmonary disease (COPD) treatment.
The product is indicated for the long-term maintenance bronchodilator treatment of airflow obstruction in adult patients with COPD, including chronic bronchitis and/or emphysema.
Novartis Pharmaceuticals president Andre Wyss said Arcapta Neohaler represents an important new treatment option for the 14 million Americans living with COPD.
"The launch of Arcapta Neohaler is a significant milestone as we continue to establish a strong respiratory presence in the US market," Wyss added.